{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:32Z","timestamp":1793228132064,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Subcutaneous (SC) administration of the anti-CD38 antibody isatuximab (Isa) by an on-body delivery system (OBDS), plus pomalidomide-dexamethasone, has demonstrated safety and efficacy comparable to intravenous (IV) administration, with no infusion reactions and excellent local tolerability in multiple myeloma (MM) patients. We report here results of a nurse survey designed to evaluate convenience of treatment with SC Isa, via OBDS, for healthcare providers and MM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A newly developed, expert-vetted questionnaire was used to survey nurses with experience in SC administration to MM patients enrolled in clinical trials. Results on extent of agreement with pre-vetted statements were expressed as percentages of respondents. Free-text answers were analyzed for each respondent and grouped by topic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All surveyed nurses (N=12) agreed that OBDS administration improved efficiency and was easy to learn and administer with a low level of physical burden, leading to a preference for OBDS over IV Isa administration and facilitating a positive treatment experience for the patients. Compared with IV dosing, the OBDS improved patient comfort and could reduce time spent in the clinic. As agreed by most nurses, main advantages for patients included no needle visibility, short treatment duration, and a generally well-tolerated and painless SC injection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings show a high level of confidence among nurses in SC Isa administration via OBDS, due to the ease of use, tolerability, and time savings achieved with hands-free OBDS injections. Our findings suggest applicability of the OBDS for convenient SC Isa administration to MM patients in routine clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1547108","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:47:02Z","timestamp":1750225622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey"],"prefix":"10.3389","volume":"15","author":[{"given":"Nuria","family":"S\u00e1nchez Avello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Calvo Pajares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Suzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Barlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14737140.2021.1837627","article-title":"Monoclonal antibodies as an addition to current myeloma therapy strategies","volume":"21","author":"Jullien","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"HemaSphere"},{"key":"B4","unstructured":"NCCN Guidelines, multiple myeloma. Version 1.2025"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"IMROZ Study Group. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","unstructured":"Sarclisa\u00ae (isatuximab-irfc) injection, for intravenous use. Prescribing information\n          \n          Bridgewater, NJ, USA\n          Sanofi\n          \n          2024"},{"key":"B13","unstructured":"Sarclisa EPAR - Product information\n          \n          \n          \n          2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1188\/19.ONF.E38-E47","article-title":"Administration of subcutaneous monoclonal antibodies in patients with cancer","volume":"46","author":"Rodrigues Ferreira","year":"2019","journal-title":"Oncol Nurs Forum"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40259-023-00626-1","article-title":"Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access","volume":"38","author":"Bittner","year":"2024","journal-title":"BioDrugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2249232","article-title":"Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review","volume":"23","author":"Parra","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","article-title":"A Systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting","volume":"7","author":"McCloskey","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284730","article-title":"A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"109","author":"Quach","year":"2024","journal-title":"Haematologica"},{"key":"B19","unstructured":"GMMG-HD8\/DSMM XIX trial. Lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in patients with newly diagnosed multiple myeloma; NCT05804032\n          \n          ClinicalTrials.gov"},{"key":"B20","unstructured":"SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM (IRAKLIA). NCT05405166\n          \n          ClinicalTrials.gov"},{"key":"B21","unstructured":"A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and\/or refractory multiple myeloma. NCT05704049"},{"key":"B22","unstructured":"A study to investigate subcutaneous isatuximab in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and\/or refractory multiple myeloma (SubQSA). NCT06356571"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.004","article-title":"Recent developments in convenience of administration of the anti-CD38 antibody isatuximab: subcutaneous delivery and fast intravenous infusion in patients with multiple myeloma","volume":"24","author":"Quach","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B24","unstructured":"Adherence to long-term therapies: evidence for action\n          \n          \n          \n          2003"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2484278","article-title":"Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study","volume":"32","author":"Desai","year":"2025","journal-title":"Drug Delivery"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1547108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:47:05Z","timestamp":1750225625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1547108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1547108"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1547108","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1547108"}}